High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors-Reference-Cited by-同舟云学术

High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Published:2023-12 Issue: Volume:186 Page:107417
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Manglaviti Sara,Bini Marta,Apollonio Giulia,Zecca Ernesto,Galli Giulia,Sangaletti Sabina,Labianca Alice,Sottotetti Elisa,Brambilla Marta,Occhipinti Mario,Proto Claudia,Prelaj Arsela,Signorelli Diego,De Toma Alessandro,Viscardi Giuseppe,Beninato Teresa,Mazzeo Laura,Bottiglieri Achille,Leporati Rita,Fotia Giuseppe,Ganzinelli Monica,Portararo Paola,Garassino Marina Chiara,de Braud Filippo G.M.,Lo Russo Giuseppe,Torri Valter,Ferrara Roberto

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. The 2015 World Health Organization Classification of Lung Tumors;Travis;J. Thorac. Oncol.,2015

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

3. Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13;Katakami;J. Thorac. Oncol.,2014

4. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials;LeVasseur;Cancer Treat. Rev.,2016

5. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group;Rosen;J. Clin. Oncol.,2003